Najat Khan Sells 124,403 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) insider Najat Khan sold 124,403 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares of the company’s stock, valued at $2,695,105.35. This trade represents a 16.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $4.11 on Wednesday. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -2.28 and a beta of 0.94. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The stock’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $5.10.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The firm’s revenue for the quarter was down 80.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.34) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after purchasing an additional 6,699 shares during the period. Invesco Ltd. raised its holdings in shares of Recursion Pharmaceuticals by 13.4% during the 1st quarter. Invesco Ltd. now owns 202,531 shares of the company’s stock valued at $1,071,000 after buying an additional 23,912 shares during the period. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $36,000. Ieq Capital LLC boosted its holdings in Recursion Pharmaceuticals by 56.3% in the 1st quarter. Ieq Capital LLC now owns 53,228 shares of the company’s stock worth $282,000 after acquiring an additional 19,180 shares during the period. Finally, Royal Bank of Canada boosted its holdings in Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after acquiring an additional 232,038 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.50.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.